Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008
NCT ID: NCT01333462
Last Updated: 2011-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
199 participants
INTERVENTIONAL
2009-03-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer
NCT01354379
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
NCT01430819
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
NCT00772109
Strategies for Enhancing Mucosal Immunity to Influenza Vaccine
NCT01385215
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00835926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phosphate Buffered Saline (PBS) IN
Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Fluzone 4 mcg HA IN
Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Fluzone 15 mcg HA IM
Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
NB-1008 4 mcg HA 5% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 4 mcg HA 10% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 4 mcg HA 15% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 4 mcg HA 20% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Fluzone 10 mcg HA IN
Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
NB-1008 10 mcg HA 5% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 10 mcg HA 10% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 10 mcg HA 15% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
NB-1008 10 mcg HA 20% W805EC
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NB-1008
NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
Control
The controls include PBS placebo control as well as Fluzone IN and IM active controls.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Are 18-49 years of age, inclusive.
3. If female, must be non-pregnant as confirmed by a negative serum pregnancy test conducted at screening and a negative urine pregnancy test conducted at the site within 24 hours preceding receipt of vaccine.
4. Females who are not surgically sterile or at least one year post-menopausal agree to use oral, implantable, transdermal or injectable contraceptive or another reliable form of contraception approved by the Investigator for a minimum of 30 days prior to vaccination and for 3 months following vaccination.
5. Healthy, as determined by medical history, physical examination, vital signs, and clinical laboratory examinations.
6. Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
7. Has given written informed consent to participate in the study.
Exclusion Criteria
2. Receipt of the 2008-2009 influenza vaccine.
3. Positive serology for HIV-1 or HIV-2, or HCV antibodies.
4. Platelet count \<150,000/mm3.
5. Positive urine drug screen.
6. History of aspiration, dysphagia, swallowing disorders, stroke or other neurologic conditions that may predispose the subject to aspiration of test articles into the respiratory tract.
7. History of Bell's palsy.
8. Cancer or treatment for cancer, within 3 years. Subjects with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Basal cell carcinoma (BCC) or (SCC) are allowed, unless present on or near the nose.
9. Impaired immune responsiveness, regardless of cause, including diabetes mellitus.
10. Presently receiving or history of receiving any medications or treatments that affects the immune system such as immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months.
11. Chronic use of inhaled or intranasal sprays including decongestants and corticosteroids.
12. Presently a smoker or tobacco user or have a history of smoking or tobacco use within the past year prior to screening.
13. Receipt or planned administration of a nonstudy vaccine within 30 days before the study, including licensed influenza vaccines and prior to the Day 60 telephone contact. Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) up to 8 days before or at least 8 days after a dose of study vaccine will be allowed. Administration of study vaccine can be delayed if a nonstudy vaccine has been administered and will be given as soon as acceptable, as described above.
14. Known allergy to any vaccine component, including eggs, egg products, or thimerosal.
15. History of allergic and/or anaphylactic type reaction to injected vaccines or to any of the components of NB-1008 \[soybean oil, dehydrated alcohol (anhydrous ethanol), polysorbate (Tween 80) and cetylpyridinium chloride (CPC)\].
16. History of drug or chemical abuse in the year before the study.
17. Receipt of any investigational product or nonregistered drug within the 30 days before study entry or currently enrolled in any investigational drug study or intends to enroll in such a study within the ensuing 6 month period.
18. Use of nasally administered prescription or over-the-counter (OTC) medications within 7 days before vaccination
19. Receipt of blood or blood products 8 weeks before study entry or planned administration prior to the Day 60 telephone contact.
20. Donation of blood or blood products within 8 weeks before study entry or at any time up to the Day 28 clinic visit.
21. Acute disease within a week prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination) with or without fever. For subjects with a minor illness, such as diarrhea, or mild upper respiratory tract infection with or without low-grade febrile illness, the subject can be re-screened once they have complexly recovered.
22. Any condition that, in the opinion of the investigator, might interfere with study objectives.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NanoBio Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NanoBio Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johnson County Clin-Trials
Lenexa, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NB-1008-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.